JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, C. J.
Right arrow Articles by Nieduzak, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C. J.
Right arrow Articles by Nieduzak, T. R.

5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4- methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa

CJ Schmidt, VL Taylor, GM Abbate and TR Nieduzak

Merrell Dow Research Institute, Cincinnati, Ohio.

The active and inactive stereoisomers of the serotonin (5-HT2) antagonist, MDL 11,939, were used to examine the relationship between the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on the dopaminergic system and its long-term effects on the serotonergic system. Only the R-(+) stereoisomer of MDL 11,939 both reversed the acute stimulation of striatal dopamine synthesis by MDMA and prevented the deficit in forebrain 5-HT concentrations measured one week later. This acute activation of striatal dopamine synthesis by MDMA is a compensatory response to the carrier-mediated efflux of transmitter as shown by its sensitivity to the dopamine uptake inhibitor, nomifensine. It is suggested that in the absence of this enhanced synthesis, the dopaminergic neuron cannot sustain the carrier-mediated dopamine release which is a prerequisite for the development of MDMA-induced neurotoxicity. This hypothesis is supported by the observation that the administration of the dopamine precursor, L-dopa, with MDMA reverses the protective effects of 5-HT2 receptor antagonists.

Volume 256, Issue 1, pp. 230-235, 01/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
N. Easton and C. A. Marsden
Ecstasy: Are animal data consistent between species and can they translate to humans?
J Psychopharmacol, March 1, 2006; 20(2): 194 - 210.
[Abstract] [PDF]

Home page
 Pharmacol. Rev.Home page
A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Aguirre, M. Barrionuevo, B. Lasheras, and J. Del Río
The Role of Dopaminergic Systems in the Perinatal Sensitivity to 3,4-Methylenedioxymethamphetamine-Induced Neurotoxicity in Rats
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1159 - 1165.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.